Tag: Immutep Limited
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Featured Article
Good Design Australia opens entries for 2026 awards
For more than six decades, Good Design Australia has celebrated the power of design to shape innovation, industry, and everyday life. Its flagship program, the Australian Good Design Awards, recognises projects that show how thoughtful design can enhance products, services, systems, and communities.
